We are looking forward to tomorrow as we present clinical data from the RUBY trial of reni-cel for the treatment of severe sickle cell disease at #EHA2024. Learn more: bit.ly/3VikpC6 #sicklecelldisease #geneediting #biotechnology
Editas Medicine
Biotechnology Research
Cambridge, Massachusetts 43,698 followers
What If You Could Repair Broken Genes?
About us
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
- Website
-
http://www.editasmedicine.com
External link for Editas Medicine
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2013
- Specialties
- Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
Locations
-
Primary
11 Hurley St
Cambridge, Massachusetts 02141, US
-
4909 Nautilus Ct N
Suite 208/211
Boulder, Colorado 80301, US
Employees at Editas Medicine
Updates
-
Earlier today, we announced new safety and efficacy data from the EdiTHAL trial of reni-cel in 7 patients with transfusion-dependent beta thalassemia, presented at #EHA2024. Read the press release for details: https://bit.ly/4ckMb7T #EHA2024 #geneediting #thalassemia
-
Today at #EHA2024, clinical data from the Phase 1/2 EdiTHAL trial of reni-cel in patients with transfusion-dependent beta thalassemia will be presented in a poster presentation. Learn more: http://bit.ly/3WBoV0T #EHA2024 #geneediting #thalassemia
-
#BREAKING: Editas Medicine reports new safety and efficacy data from the RUBY trial of reni-cel in 18 Patients with sickle cell disease, presented at the European Hematology Association (EHA) Annual Congress. Read the press release for details: https://bit.ly/3VikpC6 #EHA2024 #geneediting #sicklecelldisease
-
#BREAKING: Editas Medicine announces new safety and efficacy data from the EdiTHAL trial of reni-cel in 7 patients with transfusion-dependent beta thalassemia, presented at the European Hematology Association Annual Congress. Read the press release for details: https://bit.ly/4ckMb7T #EHA2024 #geneediting #thalassemia
-
We are excited to be in Madrid for #EHA2024! Later this week, we will be presenting clinical data from the RUBY and EdiTHAL trials of reni-cel. Learn more: bit.ly/3WBoV0T #EHA2024 #geneediting #sicklecelldisease #thalassemia
-
Editas Medicine reposted this
A heartfelt thank you to our sponsor, Editas Medicine, for their incredible support of the Sickle Cell Health Fair and Summit! Join us on Saturday, June 15, 2024, from 11 am to 4 pm at the Fifth Ward Multi-Service Center. Let’s come together to learn, share, and support our community. For more information, check the link in our bio! #SickleCellHealthFair #EditasMedicine #CommunitySupport #HealthSummit #ThankYou
-
Editas Medicine reposted this
Exciting news! 🍾 Azzur Cleanrooms on Demand™ (COD) hosted a grand opening and ribbon-cutting ceremony for its latest facility in Devens, Massachusetts, on May 16. We would like to thank MassDevelopment, MassBio, the Devens Enterprise Commission, and Editas Medicine for joining us and speaking at the event. 👏 This new facility will offer advanced, innovative approaches that will continue to enable the development and manufacturing of major brands in the life sciences industry and create approximately 60 jobs, including staff positions and support services! Read more in the full press release here: https://azzur.co/3X3PKef #LifeSciences #Cleanrooms #GxPManufacturing
-
Congrats to our team of Editors who presented preclinical data demonstrating several in vivo capabilities towards developing transformative in vivo gene editing medicines at #ASGCT24 earlier this month! In case you missed it, visit our website to view our presentations: https://bit.ly/3wR3jht #geneediting #invivo #biotechnology
-
Yesterday, we announced we will present clinical data from the RUBY and EdiTHAL trials of reni-cel at the European Hematology Association 2024 Congress in June. Learn more: https://bit.ly/3WBoV0T #EHA2024 #geneediting #sicklecelldisease #thalassemia